These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19107111)

  • 1. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
    van den Hout WB
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of biologics in early rheumatoid arthritis.
    Finckh A; Bansback N; Liang MH
    Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
    [No Abstract]   [Full Text] [Related]  

  • 5. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
    Boers M
    Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key.
    den Broeder N; Bouman CAM; Kievit W; van Herwaarden N; van den Hoogen FHJ; van Vollenhoven RF; Bijlsma HWJ; van der Maas A; den Broeder AA
    Ann Rheum Dis; 2019 Jan; 78(1):141-142. PubMed ID: 30150367
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
    Curtis JR; Singh JA
    Clin Ther; 2011 Jun; 33(6):679-707. PubMed ID: 21704234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
    Pressman Lovinger S
    JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
    [No Abstract]   [Full Text] [Related]  

  • 12. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic evaluation of a new treatment for rheumatoid arthritis].
    Suka M; Yoshida K
    Nihon Rinsho; 2007 Jul; 65(7):1327-30. PubMed ID: 17642251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.
    Zimmermann M; Vodicka E; Holman AJ; Garrison LP
    J Med Econ; 2018 Jul; 21(7):712-720. PubMed ID: 29701508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis: out of touch with clinical reality?
    Maetzel A
    Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.